Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000717 · ClinicalTrials.gov registry record · NA
The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS
A NA study of HIV Infections and Pneumonia, Pneumocystis Carinii, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT00000717 is a NA study of HIV Infections and Pneumonia, Pneumocystis Carinii that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 50 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT00000717, a NA study of HIV Infections and Pneumonia, Pneumocystis Carinii, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
To determine the safety and effectiveness of clindamycin and primaquine in the treatment of mild Pneumocystis carinii pneumonia (PCP) in AIDS patients. As many as 80 percent of AIDS patients experience at least one episode of PCP and about one-third of these patients have a recurrence of the disease. Drugs currently used for treatment of acute PCP are toxic to the majority of AIDS patients. The combination of clindamycin and primaquine reduces the numbers of PCP organisms in laboratory tests and in animal studies. Both drugs can be given orally, concentrate in lung tissue, and have been used safely in humans for treatment of other diseases. It is possible that the combination may prove to be as good or better than standard therapy for PCP and side effects may be less.
Conditions Studied
Interventions
- DRUG Clindamycin
- DRUG Primaquine
Study Locations (7)
California
- Los Angeles County - USC Med Ctr - Los Angeles
- San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco
Illinois
- Northwestern Univ Med School - Chicago
- Rush Presbyterian - Saint Luke's Med Ctr - Chicago
Ohio
- Univ Hosp of Cleveland / Case Western Reserve Univ - Cleveland
- Ohio State Univ Hosp Clinic - Columbus
Indiana
- Indiana Univ Hosp - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Est. Completion | 1991-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000717
The ClinicalTrials.gov registry entry for NCT00000717 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Clindamycin is the first listed.
NCT00000717 reports 7 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, Ohio.
Frequently Asked Questions
What is clinical trial NCT00000717 about?
NCT00000717 is a clinical study titled "The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS". To determine the safety and effectiveness of clindamycin and primaquine in the treatment of mild Pneumocystis carinii pneumonia (PCP) in AIDS patients. As many as 80 percent of AIDS patients experience at least one episode of PCP and about one-third of these patients have a recurrence of the diseas...
What is the current status of trial NCT00000717?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. Estimated completion is 1991-11.
What conditions does trial NCT00000717 study?
This clinical trial studies the following conditions: HIV Infections, Pneumonia, Pneumocystis Carinii.
What interventions are being tested in trial NCT00000717?
The interventions under investigation include: Clindamycin (DRUG), Primaquine (DRUG).
Who is sponsoring clinical trial NCT00000717?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000717 being conducted?
This trial has 7 study locations across California, Illinois, Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.